Cosmos Health Inc. (COSM) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cosmos Health Inc. is an international healthcare group headquartered in Thessaloniki, Greece, operating in the pharmaceutical, nutraceutical, and healthcare distribution sectors. The company operates through reportable segments including Wholesale, Pharma Manufacturing, and Nutraceuticals & Pharmaceuticals. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $17,110,425 | $12,411,048 | $45,568,655 | $40,202,238 |
| Gross Profit | $2,602,618 | $1,206,862 | $5,816,231 | $3,307,736 |
| Gross Margin | 15.2% | 9.7% | 12.8% | 8.2% |
| Net Loss | $(5,352,890) | $(2,182,534) | $(8,999,055) | $(6,639,935) |
| Operating Cash Flow | N/A | N/A | $(3,851,273) | $(3,883,215) |
| Cash & Restricted Cash | $4,633,660 (as of Sept 30, 2025) | |||
| Total Debt (Current + Long Term) | ~$19.3M (Notes, Convertibles, Lines of Credit) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 37.8% quarter-over-quarter and 13.4% year-to-date, driven by expansion in the UAE, growth in contract manufacturing (Cana S.A.), and new pharmacy clients for Cosmofarm S.A.
- Margin Expansion: Gross margin improved significantly to 15.2% in Q3 2025 from 9.7% in Q3 2024, attributed to a favorable sales mix with higher-margin nutraceuticals and contract manufacturing.
- Net Loss Increase: Net loss widened substantially due to significant non-cash charges not present in the prior year, including a $2.18M loss on the change in fair value of convertible notes and a $0.31M loss on derivative liabilities.
- Liquidity Position: Total cash and restricted cash increased to $4.63M from $0.32M at year-end 2024. However, $3.74M of this is restricted cash designated for the purchase of digital assets (Ethereum) per a convertible note agreement.
- Debt Structure: The company issued $9.84M in new convertible notes during the nine-month period, including an $8M senior secured note in August 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months due to accumulated deficits ($123M) and negative operating cash flows. This is partially mitigated by recent financing ($8M note closing) and ATM equity sales.
- Unusual Items:
- Convertible Note Fair Value: A $2.18M non-cash loss in Q3 2025 related to mark-to-market adjustments on convertible notes.
- Digital Assets: The company purchased $1M of Ethereum in Q3 2025 and adopted new accounting standards (ASU 2023-08) to measure crypto assets at fair value.
- Stock-Based Compensation: Significant expense of $1.73M YTD 2025 related to equity awards and debt settlements.
- Outlook: The company plans to expand distribution in the UAE, grow the Cosmofarm customer base, and secure new contract manufacturing agreements. It is pursuing amendments to debt facilities to defer principal repayments.
- Risks:
- Dependence on external financing to meet obligations.
- Material weaknesses in internal controls over financial reporting (segregation of duties, ITGCs).
- Exposure to foreign currency fluctuations (EUR/GBP vs USD).
Investor Verification Checklist
- Restricted Cash Usage: Verify the specific terms and covenants of the August 2025 convertible note requiring $3.74M of cash to be held for Ethereum purchases.
- Debt Covenants: Review the $8M senior secured note covenants, specifically the requirement to maintain $400,000 in available cash and the 9% interest rate.
- Internal Controls: Assess the remediation plan for material weaknesses in internal controls, which management expects to complete by December 31, 2025.
- Related Party Transactions: Scrutinize the significant balances with Doc Pharma S.A. (related to the CEO's family), including $4M in prepaid expenses and $2.8M in receivables.
- Going Concern Mitigation: Monitor the execution of the $300M convertible note facility and the success of the At-The-Market (ATM) equity program to ensure liquidity sufficiency.